TY  - BOOK
AU  - DeKlotz, Timothy R
AU  - Khan, Amir
TI  - Linear IgA Disease of the Gingiva Following Nivolumab Therapy
SN  - 1524-9557
PY  - 2019///
KW  - *Antineoplastic Agents, Immunological/ae [Adverse Effects]
KW  - *Gingival Diseases/et [Etiology]
KW  - *Immunoglobulin A
KW  - *Nivolumab/ae [Adverse Effects]
KW  - Aged
KW  - Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
KW  - Humans
KW  - Lung Neoplasms/dt [Drug Therapy]
KW  - Male
KW  - MedStar St Mary's Hospital
KW  - MedStar Washington Hospital Center
KW  - Otolaryngology
KW  - Journal Article
N1  - Available online from MWHC library: 2000 - present
N2  - Immunotherapy has advanced the treatment of solid organ malignancies. Although generally well tolerated, treatment with immune checkpoint inhibitors can be complicated by immune-related adverse events, some of which are relatively uncommon. We report the first case of gingival linear immunoglobulin A disease related to treatment with an antiprogrammed cell death protein 1 antibody. A 73-year-old male with advanced non-small cell lung cancer achieved a durable response to nivolumab monotherapy. After 1 year of treatment, he developed gingival swelling and pain. Biopsy revealed linear immunoglobulin A disease of the gingiva which was effectively treated with systemic steroids. Ongoing vigilance for immune-mediated toxicity is paramount during and after treatment with immune checkpoint inhibitors
UR  - https://dx.doi.org/10.1097/CJI.0000000000000288
ER  -